Omi Parikh

10.3k total citations
34 papers, 590 citations indexed

About

Omi Parikh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Omi Parikh has authored 34 papers receiving a total of 590 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Omi Parikh's work include Renal cell carcinoma treatment (14 papers), Prostate Cancer Treatment and Research (13 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Omi Parikh is often cited by papers focused on Renal cell carcinoma treatment (14 papers), Prostate Cancer Treatment and Research (13 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Omi Parikh collaborates with scholars based in United Kingdom, France and United States. Omi Parikh's co-authors include Bernard Escudier, Ugo De Giorgi, Faisal Mehmud, Petri Bono, Sadya Khan, Emmanuel Sevin, David Cella, Camillo Porta, Jose Diaz and Robert D. Hawkins and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Omi Parikh

31 papers receiving 579 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Omi Parikh United Kingdom	11	461	306	226	224	89	34	590
Daniel Yick Chin Heng Canada	11	597 1.3×	302 1.0×	396 1.8×	261 1.2×	138 1.6×	110	759
Sangeeta Jethwa Switzerland	5	582 1.3×	480 1.6×	253 1.1×	359 1.6×	68 0.8×	10	757
Sandhya Srinivas United States	9	396 0.9×	250 0.8×	479 2.1×	199 0.9×	78 0.9×	18	748
Vincenzo Emanuele Chiurì Italy	12	456 1.0×	213 0.7×	478 2.1×	189 0.8×	67 0.8×	35	703
Guillaume Mouillet France	11	319 0.7×	146 0.5×	212 0.9×	105 0.5×	77 0.9×	33	465
Raffaele Ratta Italy	17	435 0.9×	197 0.6×	327 1.4×	185 0.8×	82 0.9×	65	602
Davide Bimbatti Italy	13	398 0.9×	173 0.6×	205 0.9×	158 0.7×	80 0.9×	56	560
Milan Mangeshkar United States	9	369 0.8×	217 0.7×	289 1.3×	165 0.7×	55 0.6×	17	655
Valentina Guadalupi Italy	14	385 0.8×	297 1.0×	225 1.0×	180 0.8×	194 2.2×	45	637
Brenda Dickow United States	11	280 0.6×	162 0.5×	215 1.0×	94 0.4×	57 0.6×	20	449

Countries citing papers authored by Omi Parikh

Since Specialization

Citations

This map shows the geographic impact of Omi Parikh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omi Parikh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omi Parikh more than expected).

Fields of papers citing papers by Omi Parikh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omi Parikh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omi Parikh. The network helps show where Omi Parikh may publish in the future.

Co-authorship network of co-authors of Omi Parikh

This figure shows the co-authorship network connecting the top 25 collaborators of Omi Parikh. A scholar is included among the top collaborators of Omi Parikh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omi Parikh. Omi Parikh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bahl, Amit, Amarnath Challapalli, Prantik Das, et al.. (2025). Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter RECOMMEND study.. Journal of Clinical Oncology. 43(5_suppl). 89–89.

Evans, D. Gareth, George J. Burghel, Hélene Schlecht, et al.. (2025). UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first results. PubMed. 4(1). e000592–e000592. 1 indexed citations

Bahl, Amit, Amarnath Challapalli, Alison Birtle, et al.. (2024). Multi-centre prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) or enzalutamide (ENZ): The ACE study.. Journal of Clinical Oncology. 42(4_suppl). 20–20.

Fizazi, Karim, Guilhem Roubaud, Alice Bernard‐Tessier, et al.. (2024). MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results.. Journal of Clinical Oncology. 42(4_suppl). 159–159. 1 indexed citations

Arranz, José Ángel, Omi Parikh, Laura-Maria Krabbe, et al.. (2024). Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis. Current Oncology Reports. 26(12). 1639–1650. 1 indexed citations

Allison, Jennifer, Sam Wong, Helen Wong, et al.. (2023). Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis. Targeted Oncology. 18(4). 593–599. 1 indexed citations

Fizazi, Karim, Alice Bernard‐Tessier, Guilhem Roubaud, et al.. (2023). Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer. NEJM Evidence. 3(1). EVIDoa2300171–EVIDoa2300171. 13 indexed citations

Hussain, Syed A., J.F. Lester, Richard A. Jackson, et al.. (2022). Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 20 indexed citations

Fizazi, Karim, Alice Bernard‐Tessier, Philippe Barthélémy, et al.. (2022). 1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients. Annals of Oncology. 33. S1165–S1165. 2 indexed citations

10.

Bjartell, Anders, Luís Costa, Gero Kramer, et al.. (2022). Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry. European Urology Open Science. 45. 12–22. 7 indexed citations

11.

Lindskog, Magnus, Anna Laurell, Anders Kjellman, et al.. (2022). Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science. 40. 38–45. 8 indexed citations

12.

Motzer, Robert J., Paul Russo, Viktor Gruenwald, et al.. (2022). LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial. Annals of Oncology. 33. S1430–S1430. 28 indexed citations

13.

Crabb, Simon J., Syed A. Hussain, Samantha Hinsley, et al.. (2022). A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.. Journal of Clinical Oncology. 40(6_suppl). 436–436. 17 indexed citations

14.

Attard, Gerhardt, Louise Brown, Nigel Clarke, et al.. (2021). LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Annals of Oncology. 32. S1298–S1298. 5 indexed citations

15.

Lindskog, Magnus, Anna Laurell, Anders Kjellman, et al.. (2020). A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.. Journal of Clinical Oncology. 38(5_suppl). 11–11. 11 indexed citations

16.

Song, Yee Pei, et al.. (2017). Comparing Clinical Outcomes for Radium-223: Do Older Patients Do Worse?. International Journal of Radiation Oncology*Biology*Physics. 98(4). 955–957. 6 indexed citations

17.

Song, Yi, et al.. (2017). A Comparison of Toxicities and Clinical Benefit of Radium 223 Between Different Age Groups. Clinical Oncology. 29(3). e88–e88.

18.

Parikh, Omi, et al.. (2014). Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib. Patient Preference and Adherence. 8. 503–503. 5 indexed citations

19.

Parikh, Omi, et al.. (2011). Case of Rhabdomyosarcoma Presenting With Myasthenia Gravis. Journal of Clinical Oncology. 29(22). e653–e655. 3 indexed citations

20.

Parikh, Omi, et al.. (2008). Severe Thrombocytopenia Induced by a Single Infusion of Trastuzumab. Clinical Breast Cancer. 8(3). 285–286. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact